Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCHE | P06276 | 4/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 2/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.31 |
| ▸ | MEN1 | O00255 | 2/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9912673 | 0.95 | BCHE (0.38) | BCHESMN1; SMN2KDM4EALDH1A1MEN1 | |
| SCHEMBL11974084 | 0.89 | MAPT (0.31) | BCHESMN1; SMN2 | |
| SCHEMBL11974081 | 0.89 | MAPT (0.31) | BCHESMN1; SMN2 | |
| SCHEMBL11974087 | 0.89 | MAPT (0.31) | BCHESMN1; SMN2 | |
| SCHEMBL1341780 | 0.79 | CES2 (0.39) | SMN1; SMN2KDM4EGAATSHRALDH1A1 | |
| SCHEMBL27393519 | 0.79 | LMNA (0.44) | BCHESMN1; SMN2TSHRALDH1A1 | |
| SCHEMBL12023144 | 0.78 | SMN1; SMN2 (0.42) | BCHESMN1; SMN2KDM4EALDH1A1MEN1 | |
| SCHEMBL18573688 | 0.77 | CES2 (0.42) | SMN1; SMN2KDM4ETSHRALDH1A1 | |
| SCHEMBL18214886 | 0.77 | CES2 (0.42) | SMN1; SMN2KDM4ETSHRALDH1A1 | |
| SCHEMBL65733 | 0.77 | CES2 (0.42) | SMN1; SMN2KDM4ETSHRALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200157092-A1 | [1,2,4]-TRIAZOLO [1,5-A]-PYRIMIDINYL DERIVATIVES SUBSTITUTED WITH PIPERIDINE, MORPHOLINE OR PIPERAZINE AS OGA INHIBITORS | Janssen Pharmaceutlca NV (BE) | 2020-05-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200157092-A1 | [1,2,4]-TRIAZOLO [1,5-A]-PYRIMIDINYL DERIVATIVES SUBSTITUTED WITH PIPERIDINE, MORPHOLINE OR PIPERAZINE AS OGA INHIBITORS | OGA, PSEN1, PSEN2 | BCHE 234/4885SMN1; SMN2 55/4885KDM4E 1840/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.